Purpose: To study the clinical effect of a topical controlled-release ophthalmic fluconazole liposomal formulation on patients with Candida keratitis.
T he treatment of fungal keratitis is often disappointing because of limited tissue penetration, a narrow antimicrobial spectrum, and toxicity of the currently available antifungal agents. 1 Fungal infections of the cornea, especially Candida, are considered a major problem in ophthalmology because of diagnostic and therapeutic difficulties. Fungal keratitis can impair vision or lead to total blindness, so various specific antifungal agents have been used. 2 Fungal keratitis is not rare in Egypt, especially in the countryside regions, and it represents infection of the cornea that can potentially cause blindness. 3 The high incidence of fungal keratitis is attributed to the agricultural environment and suitable high temperature, which contribute to the abundance of fungi in the surrounding environment. Also, occupational trauma of plant origin or with a hard object during farming, the major economic activity of the population, misdiagnosis, and delayed presentation aggravate the problem. Early diagnosis and adequate dosing of antifungals are essential to prevent recourse to therapeutic penetrating keratoplasty. 4 Liposomes are artificial closed vesicles consisting of lipid bilayers (or lamellae) enclosing an equal number of aqueous compartments. 5 Vesicular drug-delivery systems used in an ophthalmic carrier, such as liposomes and niosomes, help in providing prolonged and controlled action at the corneal surface and preventing the metabolism of the drug by enzymes present at the tear/corneal surface. 6 The discovery of liposomes has opened up new opportunities for novel applications in ocular drug delivery; their efficacy as vectors and their ability to increase ocular absorption have ensured their success. Liposomes offer advantages over most ophthalmic delivery systems in being completely biodegradable and relatively nontoxic. Fluconazole is a bis-triazole compound that exhibits a broad-spectrum antifungal activity belonging to the group of triazoles. It is effective against many fungal species, including Candida. 7 It acts as a fungistatic agent. The high penetration into the aqueous humor and low toxicity and safety of fluconazole make it a good candidate for consideration as a topical ocular antifungal agent. 8, 9 Controlled-release topical fluconazole-loaded liposomes had been tried by our group in rabbits and good results were achieved. 10 This study is a continuation of our previously published work and we aim to show the clinical effect of the same formula, which was used before in rabbits, in patients with Candida keratitis.
MATERIALS AND METHODS
All of the steps in preparation of the fluconazole-loaded liposome eye drops were performed under aseptic conditions. Fluconazole liposomes were prepared using the reverse-phase evaporation technique. 11 Fluconazole eye drops were prepared by diluting the optimized liposome preparations with Sørensen's modified phosphate buffer, pH 7, containing 0.01% benzalkonium chloride as preservatives, so that the eye drops contained equivalent amounts of 0.2% of fluconazole-loaded liposomes. We suspected Candida keratitis in 20 patients. For all of these patients, we discontinued any previous medications for 48 hours and then cultures for bacteria and fungi were prepared. After obtaining samples for culture, we immediately started with both 0.3% gatifloxacin eye drops every hour for the first 24 hours and 4 times daily after that and with fluconazole-loaded liposomes 3 times a day, 1% cyclopentolate 3 times a day, and bandage, until the results of the cultures confirmed the Candida albicans diagnosis, which took an average (SD) time of 8 days (63 days). Only 11 patients proved to have Candida keratitis with laboratory cultures. For these patients, we continued on the regimen of fluconazole-loaded liposomes (2 mg/mL) 3 times daily for 1 month besides the cyclopentolate 3 times a day and stopped gatifloxacin because of its previously reported antifungal activity. 12 The response to the treatment was divided into 3 categories: 1. Complete improvement: complete healing (closure of the epithelial defect) with scar formation at the end of 1 month. 2. Partial improvement: decrease in the ulcer size at the end of 1 month.
No improvement: included extension of ulcer size and/or
perforation that necessitated other approaches of management.
The patients were admitted to the hospital and examined daily over a 30-day period by slit lamp for signs of improvement of the hypopyon and the size of the ulcer. Best-corrected visual acuity in decimal notation was measured before starting the treatment and after 1 month. Photographs were taken before starting the treatment and 1 month after to document signs of improvement. The study was conducted after institutional board approval was attained.
RESULTS
We examined 20 eyes of 20 patients with clinically suspected Candida keratitis and the cultures of only 11 patients tested positive for C. albicans; the remaining 9 patients were excluded because their cultures tested negative. Therefore, 11 patients (7 men and 4 women) with proven Candida keratitis were included in this study (Fig. 1) .
Six of our patients had a history of trauma by objects of plant origin during work in the countryside. They all underwent laboratory workup to confirm the diagnosis. Three of the included patients in this study had diabetes mellitus for more than 15 years, and 2 patients had rheumatoid arthritis and were under systemic steroid therapy for more than 3 years. Mean corneal ulcer diameter (mean of both horizontal and vertical diameters) was 5.5 mm (range, 3.5-6.5 mm) and changed to 1.3 mm (range, 0-6.5 mm) after treatment. The time range for ulcers to heal was from 3 to 4 weeks. The mean duration of ulcer at presentation was 7.6 days (range, 3-14 days). Eight patients (73%) improved after 1 month, whereas 1 patient had partial improvement (9%) and 2 patients (18%) did not improve and underwent amniotic membrane transplantation. One of the nonimproved patients progressed to perforation 1 month after amniotic membrane transplantation and keratoplasty was performed. Mean Snellen decimal notation best-corrected visual acuity was 0.06, which was minimally improved to 0.08 at the end of the study (Table 1) . As noted by patients, the only side effect was that the eye drops exhibited a stinging sensation at the beginning of their use. The healing ulcer was associated with heavy dense scarring in some patients.
DISCUSSION
The availability of an effective and convenient treatment for fungal keratitis has become an urgent need. Several azole compounds are available for the treatment of Candida infections, including miconazole, ketoconazole, fluconazole, and itraconazole. 13 Fluconazole is a new triazole compound that has certain properties suggesting its use for the treatment of fungal keratitis. It acts against all pathogenic Candida species except Candida krusei. 14 The effect of topical fluconazole on experimental Candida keratitis (in vitro) or on human eyes that proved to have Candida keratitis was studied. 13, 15, 16 However, reports of its use in clinical Candida keratitis are scarce. The fluconazole eye drops were instilled every 30 minutes or 1 hour for 7 to 21 days depending on the severity. 15, 16 To overcome the tedious process of frequent instillation, the possibility of toxicity, and to accomplish patient compliance, fluconazole-loaded liposomes were prepared in the present study to exert a sustained release effect of the drug. Our previous in vitro results showed that liposomes had encouraging results in induced C. albicans infection of rabbits' corneas using only a 3 times instillation regimen. 10 Therefore, the liposomal formulations were instilled in this study 3 times daily for the period of treatment.
Seventy-three percent of patients showed a positive response with no local or systemic side effects. A decrease in the number of instillations and rapid resolution with healing ulcers emphasize the effectiveness of the drug in liposomes against deep Candida infection of the cornea.
We think that the late presentation and extensive damage to the corneal stroma at the time of presentation were responsible for partial or nonimprovement of ulcers in at least 2 of the 3 cases. Although there was minimal improvement of the visual acuity because the healing process of the ulcer was associated with dense scarring in some patients, the great role of liposomes loaded with fluconazole was in controlling the fungal infection, allowing healing, and preserving the structural integrity of the globe.
The results obtained are in accordance with those of the many researchers who found that fluconazole applied topically produced a significant antifungal effect. 15 Our previous experimental results also proved that the antifungal activity of fluconazole in liposomal formulation was better than that of fluconazole in solution. 10 Also, it was reported previously that liposomal encapsulation increases lipid solubility and hence permeability through the cell membrane. Moreover, the liposomes may enhance the binding of the drug to the active sites inside the cells. 17 In the present study, some of the most important benefits of the preparation of fluconazole in the form of liposomes were decreased instillation frequency, onset and duration of recovery, and healing from candidiasis. This gives us hope that the incidence of other infections and complications that may occur because of the long time required for an antifungal to begin working may be diminished.
The results presented herein showed that the use of topical liposomes fluconazole (2 mg/mL) as a drug-delivery system was successful in the treatment of C. albicans infection of the human cornea. The idea of fluconazoleloaded liposomes is a new one, and although the efficacy of topically applied eye drops of liposomes containing fluconazole in human mycotic keratitis has shown encouraging results, the limitation of this study is the small number of the included eyes, and a clinical trial of a large series of patients, conducted in a randomized controlled manner, is desirable to investigate the efficacy of different treatment regimens of fungal keratitis.
